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Introduction {#sec1}
============

The conversion of murine embryonic fibroblasts (MEFs) into induced neuronal cells (iNs) through forced expression of the *Brn2*, *Ascl1*, and *Myt1l* transcription factors (TFs) (hereafter called BAM \[Brn2, Ascl1, Mytl1\] factors) defined the paradigm of transdifferentiation across germ layers ([@bib28]). BAM factors synergistically cooperate in this process (∼20% efficiency), which does not require either proliferation or the transient reacquisition of pluripotency ([@bib28]). ASCL1 instructs transdifferentiation as a pioneer TF, recognizing trivalent chromatin states marked by H3 lysine 4 monomethylation (H3K4me1), lysine 9 trimethylation (H3K9me3), and lysine 27 acetylation (H3K27ac) ([@bib30]). BRN2 and MYT1L are, instead, critical for iN maturation and the suppression of alternative cell fates; upon *Ascl1*-only infection, MEFs that fail to become iNs deviate toward myocytes, an outcome that is prevented by co-transduction with *Brn2* and *Myt1l* ([@bib21], [@bib27], [@bib30]).

ASCL1 has been recently shown to effect massive remodeling of chromatin accessibility and nucleosome phasing, with open chromatin loci enriched for neuronal and muscle pathway genes ([@bib31]). Moreover, MEF-to-iN conversion features a major chromatin reconfiguration in the first 5 days after *Ascl1* induction, following which further chromatin transitions represent less than 20% of all changes underlying direct neuronal conversion ([@bib31]). This suggests that these epigenetic transitions are not as gradual as during reprogramming to pluripotency ([@bib2], [@bib4]), but the role of specific chromatin regulators in these accompanying waves of chromatin resetting remains elusive.

Here, we investigated the roles of KMT2A and KMT2B in MEF-to-iN conversion in light of their critical function in lineage decisions. KMT2A and KMT2B belong to Set1-Trithorax type H3K4 methylases, specifically responsible for the deposition of histone H3 lysine 4 trimethylation (H3K4me3) at gene promoters ([@bib5]).

Both associate with MENIN, which mediates their localization at specific loci, such as *HOX* genes ([@bib8], [@bib13], [@bib17]). Despite their high homology, KMT2A and KMT2B are spatially and temporally non-redundant. Thus, knockout (KO) of either *Kmt2a* ([@bib6]) or *Kmt2b* ([@bib8]) is embryonic lethal at embryonic day 12.5 (E12.5) or E.10.5, respectively. Furthermore, KMT2A and KMT2B have specific roles during mammalian neuronal differentiation. During retinoic acid-based differentiation, the two enzymes regulate different *HOX* genes ([@bib5]), and *Kmt2b*^−/−^ embryonic stem cells (ESCs) show a severe delay in *in vitro* differentiation toward the ectodermal lineage ([@bib20]). Adult neurogenesis and function are also specifically affected. Indeed, *Kmt2a*^−/−^ subventricular zone neural stem cells (SVZ NSCs) are impaired selectively in neuronal differentiation, whereas both KMT2A and KMT2B contribute to memory formation, albeit through distinct target pathways and with no apparent effects on brain and neuronal morphology ([@bib14], [@bib15], [@bib19]). Finally, mutations in *KMT2A* and *KMT2B* cause two distinct brain disorders: Wiedemann-Steiner syndrome, featuring intellectual disability, and a newly recognized molecular subset of early-onset generalized dystonia, respectively ([@bib22], [@bib25], [@bib32]).

Results {#sec2}
=======

Conditional Inactivation of *Kmt2a* and *Kmt2b* upon Transdifferentiation {#sec2.1}
-------------------------------------------------------------------------

To study the role of KMT2A and KMT2B during transdifferentiation, we employed conditional mouse strains carrying exon 2 of *Kmt2a* and/or *Kmt2b* flanked by LoxP sites, the knockin of the *YFP*-coding gene into one *Rosa26* allele downstream of a LoxP-flanked transcription termination cassette (STOP cassette), and the gene coding for the tamoxifen-inducible version of *Cre* recombinase knocked into the second *Rosa26* allele ([@bib8], [@bib16], [@bib26]). Upon 4-hydroxytamoxifen (4-OHT) administration, *Cre* is expressed, generating a frameshift mutation in *Kmt2a* and/or *Kmt2b* ([Figure 1](#fig1){ref-type="fig"}A). MEFs were derived from *Kmt2a* (and/or *Kmt2b*)^fl/fl^ *Cre*^+^ *YFP*^+^ embryos and from *Kmt2a*^+/+^*Kmt2b*^+/+^ *Cre*^+^ *YFP*^+^ or *Kmt2a*^fl/+^ *Cre*^+^ *YFP*^+^ for *Kmt2a* conditional KO (cKO) as controls ([Figure 1](#fig1){ref-type="fig"}A). After 5 days of 4-OHT treatment followed by either 2 or 7 days in normal medium ([Figure 1](#fig1){ref-type="fig"}B), depletion of *Kmt2a* and/or *Kmt2b* was assessed by qRT-PCR ([Figure 1](#fig1){ref-type="fig"}C) and western blot ([Figure 1](#fig1){ref-type="fig"}D).Figure 1Experimental System(A) Schematic of *Kmt2* cKO MEF derivation and 4-OHT treatment.(B) Schematic of our experimental pipeline.(C) Representative qPCR results for exon 2 copy number after 4-OHT treatment. Means ± SEM.(D) Western blot analysis for KMT2B, with VINCULIN (VCL) as housekeeping, of MEFs treated 5 days with 4-OHT and left 7 days in culture without 4-OHT. The first lane was dedicated to ESCs.

Transdifferentiation was then implemented according to the original protocol ([@bib28]; [Figure 1](#fig1){ref-type="fig"}B). The sustained expression of *YFP* ([Figure S1](#mmc1){ref-type="supplementary-material"}A) along with permanent loss of *Kmt2b* exon 2 ([Figure S1](#mmc1){ref-type="supplementary-material"}B) through the end of transdifferentiation excluded selection of *Kmt2b*^fl/fl^ iNs that might have escaped recombination.

To decipher the role of the two KMT2 methylases, we integrated two complementary approaches to capture the acquisition of iN identity along transdifferentiation: morphological analysis through an automated and unbiased imaging method (ScanR) and cytofluorimetric analysis (fluorescence-activated cell sorting \[FACS\]) for the expression of polysialic acid-neural cell adhesion molecule (PSA-NCAM), a marker of iN induction ([Figure 1](#fig1){ref-type="fig"}B). Transcriptomic and epigenomic profiling was then performed at 5 and 13 days of transdifferentiation ([Figure 1](#fig1){ref-type="fig"}B). Day 5 was chosen as reference starting point because, at this time, MEFs are still equally competent to become iNs, having all undergone convergent transcriptional changes ([@bib27]). Day 13 was selected as the endpoint because 8 days following transduction no more iNs are induced, and the 13-day iNs have been shown to be functionally mature ([@bib28]). MEFs were also profiled at the epigenomic level at the onset of transdifferentiation to define their initial chromatin configuration ([Figure 1](#fig1){ref-type="fig"}B).

*Kmt2b* Ablation Impairs Transdifferentiation {#sec2.2}
---------------------------------------------

We evaluated the transdifferentiation potential of *Kmt2a*^*−/−*^ and/or *Kmt2b*^*−/−*^ MEFs in terms of both efficiency of iN generation and degree of their maturation. To distinguish between the effect of their loss on cell mortality and transdifferentiation, we harnessed the observation that already 1 day after doxycycline administration (day 3), the vast majority of cells are post-mitotic ([@bib28]). To confidently ascribe any change in cell number to cell mortality rather than to cell proliferation, we selected cKO and control samples starting transdifferentiation from the empirically validated same number of cells on day 3.

We found that loss of *Kmt2b* greatly impaired transdifferentiation efficiency in a manner independent of the mortality rate that accompanies transdifferentiation ([Figures 2](#fig2){ref-type="fig"}A and 2B; [Table S1](#mmc1){ref-type="supplementary-material"}). In contrast, for the loss of *Kmt2a*, transdifferentiation efficiency was correlated with cell viability ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D; [Table S1](#mmc1){ref-type="supplementary-material"}), pointing to the former as a by-product of the latter.Figure 2KMT2B Is Essential for MEF-to-iN Transition(A) Efficiency of transdifferentiation in ScanR experiments, calculated relating, for any chosen concentration, the number of Tuj1^+^ at 13 days to the number of DAPI 3 days after plating.(B) Cell mortality in ScanR experiments, calculated as the ratio of DAPI 3 days (DAPI start) and 13 days (DAPI end) after plating.(A and B) *Kmt2a*^+/+^*Kmt2b*^+/+^, n = 3; *Kmt2b*^fl/fl^, n = 2; *Kmt2a*^fl/fl^*Kmt2b*^fl/fl^, n = 1.(C) Efficiency of transdifferentiation in FACS experiments, calculated relating the number of PSA-NCAM^+^ cells at 13 days to the number of plated cells.(D) Percentage of dead cells, calculated at 13 days, over the initial number of plated MEFs.(C and D) The number of independent embryos per genotype corresponds to the one reported for time point 13 days of (E).(E) Percentage of PSA-NCAM^+^ cells among transdifferentiating MEFs 5, 7, 9, 13, and 21 days after plating, assayed with FACS analysis. The number of independent embryos per time point per genotype is reported under the graph.(F) Representative images of three different experiments, each reporting the specific cKO and its control. *Kmt2a*^fl/−^ (top left), *Kmt2a*^+/+^*Kmt2b*^+/+^ (top, center and right), *Kmt2a*^−/−^ (bottom left), *Kmt2b*^−/−^ (bottom center), and *Kmt2a*^*−/−*^*Kmt2b*^−/−^ (bottom right) iNs at 13 days are reported (DAPI in blue and Tuj1 in red).(G) Representative images of 21-day *Kmt2a*^+/+^*Kmt2b*^+/+^ (left), *Kmt2a*^−/−^ (center), and *Kmt2b*^−/−^ (right) iNs acquired with the bright-field microscope.(H--J) Average neurite length per neuron, calculated with Neuritetracer on day 13 of transdifferentiation. In particular Kmt2a^−/−^ iNs (H), Kmt2b^−/−^ iNs (I), and Kmt2a^−/−^ Kmt2b^−/−^ iNs (J) were compared to controls.In the case of *Kmt2a* ScanR experiments (F and H), *Kmt2a*^fl/−^ MEFs were used as a control. In (F), (H), and (J), MEFs were plated for BAM transduction 2 days after 4-OHT, whereas, in (A)--(E), (G), and (I), MEFs were plated 7 days after 4-OHT. (A)--(E) and (H)--(J), means ± SEM; ^∗∗∗^p \< 0.0001; ^∗^p \< 0.01; ns, not significant.

Next we sought to determine whether there is any redundancy between the two methylases by knocking out both enzymes. *Kmt2a*^*−*/−^*Kmt2b*^*−*/−^ transdifferentiated MEFs showed both the highest cell death and the lowest conversion efficiency, indicating that KMT2A only partially compensates for the lack of KMT2B during transdifferentiation ([Figures 2](#fig2){ref-type="fig"}A and 2B; [Table S1](#mmc1){ref-type="supplementary-material"}). Importantly, the combined loss of *Kmt2a* and *Kmt2b* did not affect MEF viability per se but was specifically triggered upon induction of transdifferentiation ([Figures S1](#mmc1){ref-type="supplementary-material"}E and S1F).

We confirmed these observations through FACS-based quantitation of PSA-NCAM^+^ cells. Indeed, both *Kmt2a*^−/−^ and *Kmt2b*^−/−^ MEFs showed a lower efficiency of iN induction with respect to controls ([Figure 2](#fig2){ref-type="fig"}C), but although, for *Kmt2a*^−/−^ MEFs, this was entirely accounted for by the higher rate of cell death ([Figures 2](#fig2){ref-type="fig"}D, [S1](#mmc1){ref-type="supplementary-material"}G and S1H), for *Kmt2b*^−/−^ MEFs, it was independent of cell death and, thus, imputable to a specific requirement for KMT2B in transdifferentiation ([Figures 2](#fig2){ref-type="fig"}D, [S1](#mmc1){ref-type="supplementary-material"}I and S1J). Moreover, although cell mortality in *Kmt2a*^−/−^ transdifferentiating MEFs was higher with respect to *Kmt2b*^−/−^ and controls ([Figure 2](#fig2){ref-type="fig"}D), the percentage of *Kmt2a*^−/−^ PSA-NCAM^+^ cells overlapped or was even higher than in controls along the entire process ([Figure 2](#fig2){ref-type="fig"}E). This indicates that PSA-NCAM^+^ and PSA-NCAM^−^ fractions are at least equally vulnerable to cell death across *Kmt2a*^−/−^ and *Kmt2a*^+/+^.

Finally, FACS analysis of the combined KO showed that, although the viability of *Kmt2a*^−/−^*Kmt2b*^−/−^ MEFs was comparable with that of *Kmt2a*^−/−^ and lower than that of controls ([Figures 2](#fig2){ref-type="fig"}D, [S1](#mmc1){ref-type="supplementary-material"}K and S1L), their transdifferentiation efficiency was strongly reduced with respect both to control and the single cKO transdifferentiating MEFs ([Figure 2](#fig2){ref-type="fig"}C), underscoring that KMT2B is the main H3K4 trimethylase involved in direct cell conversion.

Then we analyzed the morphology of the generated iNs to probe the role of either methylase on iN maturation. To this aim, we investigated neurite elongation as a defining hallmark of complete iN conversion, finding that, in *Kmt2b*^−/−^ iNs, it was severely reduced both at 13 ([Figures 2](#fig2){ref-type="fig"}F, 2I, [S2](#mmc1){ref-type="supplementary-material"}A, and S2B) and 21 days ([Figure 2](#fig2){ref-type="fig"}G) of transdifferentiation. On the contrary, and consistent with the unaltered efficiency of iN conversion, neurite length in *Kmt2a*^−/−^ iNs was fully comparable with that of *Kmt2a*^*+*/−^ ([Figures 2](#fig2){ref-type="fig"}F, 2G, 2H, [S2](#mmc1){ref-type="supplementary-material"}C, and S2D). Finally, the few double cKO iNs only showed minimal neurite elongation ([Figures 2](#fig2){ref-type="fig"}F, 2J, and [S2](#mmc1){ref-type="supplementary-material"}E). This demonstrates that KMT2B, besides playing a fundamental role in MEF-to-iN conversion, has also a specific effect on iN maturation.

KMT2B Controls Transcriptome Resetting in MEF-to-iN Conversion {#sec2.3}
--------------------------------------------------------------

Given the role of KMT2B in H3K4me3 deposition at promoters ([@bib5]), its loss could impair the gene expression program underlying MEF-to-iN transition. To unveil the molecular basis of the dual phenotype observed upon loss of KMT2B (namely, less efficient iN conversion and defective iN maturation), we performed RNA sequencing (RNA-seq) on sorted PSA-NCAM^+^ and PSA-NCAM^−^ *Kmt2b*^−/−^ and control cells at day 13 of transdifferentiation. In particular, through the analysis of PSA-NCAM^+^ transcriptomes, we aimed to establish which genes responsible for transdifferentiation were differentially expressed in the absence of KMT2B and how *Kmt2b*^−/−^ iNs differed from controls. Instead, through PSA-NCAM^−^ transcriptomic profiling, we pursued mechanistic insight into the effect of *Kmt2b* loss on MEF-to-iN conversion.

The first component identified by principal-component analysis (PCA) clearly distinguished genotypes in both PSA-NCAM populations ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B), indicating that *Kmt2b* status represents the largest source of variation in the datasets. Specifically, through the analysis of PSA-NCAM^+^ cells, we found 1,508 differentially expressed genes (DEGs) between *Kmt2b*^−/−^ and control iNs (at false discovery rate \[FDR\] \< 0.01 and with at least a 50% fold change), the majority of which were downregulated in the latter, consistent with the gene-activating function of KMT2B ([Figure 3](#fig3){ref-type="fig"}A). To define which stage of transdifferentiation was most affected by loss of KMT2B, we clustered day 13 DEGs between *Kmt2b*^−/−^ and control iNs using K-means clustering according to their established expression pattern throughout transdifferentiation ([@bib30]; [Figure 3](#fig3){ref-type="fig"}B). Genes that are normally expressed on day 15 and downregulated on day 24 of transdifferentiation (clusters 2 and 3) were found to be already lowly expressed at 13 days in our *Kmt2b*^−/−^ samples, further highlighting a defective MEF-to-iN transition. On the other hand, a high proportion of cluster 4, whose expression gradually increases throughout transdifferentiation, peaking at day 24, and that is enriched for synaptic genes and RE1-silencing transcription factor (REST) targets (4.79-fold enrichment, q-value \[q\] ∼ 1e−54 in neuronal progenitors), was downregulated in *Kmt2b*^−/−^ iNs, further corroborating the defective neuronal fate acquisition in the absence of KMT2B.Figure 3KMT2B Loss Impairs Transcriptomic Changes Underlying Transdifferentiation(A) Volcano plot highlighting the top DEGs among *Kmt2b*^−/−^ and control 13-day iNs.(B) DEGs upon *Kmt2b* KO clustered on the basis of their expression pattern across stages of transdifferentiation (plotted are log-normalized fragments per kilobase pair per million reads sequenced \[FPKM\], scaled across the whole dataset).(C) Heatmap showing the expression across genotypes in iNs sorted at 13 days of the transcriptional regulators belonging to the three subnetworks described by [@bib27]. The significant DEGs between *Kmt2b*^*−/−*^ and the control are indicated by red arrows. Each line represents a different embryo from which the MEFs were derived.(D) Expression pattern during normal transdifferentiation (right) and across genotypes on day 13 (left) of the DEGs found in 13-day *Kmt2b*^−/−^ PSA-NCAM^−^ cells.(E) GO enrichment analysis of genes upregulated in 13-day *Kmt2b*^−/−^ PSA-NCAM^−^ cells with respect to controls.(F) *MyoD1* normalized counts in control and *Kmt2b*^−/−^ PSA-NCAM^−^ cells. Means ± SD are reported. ^∗^, FDR \< 0.01.

Recently, [@bib27] integrated the single-cell transcriptomes of *Ascl1-*only infected MEFs throughout transdifferentiation with those of 15-day BAM-infected iNs and identified the transcriptional regulators that most likely coordinate transdifferentiation progression, defining three subnetworks (i.e., MEF, initiation and maturation). We found that, in our PSA-NCAM^+^ dataset, the most disrupted subnetwork by loss of KMT2B was the maturation one, confirming at the molecular level the defective iN maturation phenotype we observed ([Figure 3](#fig3){ref-type="fig"}C). Indeed, the top 30 DEGs ([Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}C) that have annotated function(s) included four key promoters of physiological neurite extension *(Ppp1r9a*, *Myo16*, *Lrfn1*, and *Prka1b)* and nine regulators of synapse formation, maturation, and function (*Clstn3*, *Jph4*, *Syp, Sult4a1*, *Ptprn*, *Cadm3*, *Adcy1*, *Grin2b*, and *Ache*). Together, these results show that the defective iN phenotype observed upon loss of KMT2B is determined by dysregulation of the transcriptional program sustaining iN maturation.

To gain deeper insight into this phenomenon, we next compared the transcriptomes of our 13-day iNs with those of single cells undergoing MEF-to-iN transition ([@bib27]). Strikingly, *Kmt2b*^−/−^ PSA-NCAM^+^ iNs showed a higher correlation with the transcriptomes of earlier stages of transdifferentiation, providing the molecular basis for our observation that the few *Kmt2b*^−/−^ MEFs that manage to convert to iNs fail to undergo complete neuronal maturation ([Figures S3](#mmc1){ref-type="supplementary-material"}D and S3E). Furthermore, these maturation-defective iNs also present an increased correlation with myocyte gene expression, suggesting a concomitant failure to fully suppress alternative fates ([Figures S3](#mmc1){ref-type="supplementary-material"}D and S3E). Thus, to confirm whether *Kmt2b*^*−*/−^ MEFs, which transdifferentiated less efficiently than controls, switched toward the myocyte fate, we compared *Kmt2b*^*−*/−^ and control PSA-NCAM^−^ 13-day transcriptomes and found that upregulated genes in *Kmt2b*^*−*/−^ PSA-NCAM^−^ cells were significantly enriched for targets bound by ASCL1 in the first phases of transdifferentiation ([@bib30]; [Figure 3](#fig3){ref-type="fig"}D). Although these ASCL1-bound genes have been identified in MEFs transduced either with this TF alone (3.9-fold, p ∼ 2e−7) or with all BAM factors (3-fold, p ∼ 2e−10), a large fraction is then rapidly repressed by BRN2 and MYT1L in BAM-transduced MEFs ([Figure 3](#fig3){ref-type="fig"}D), preventing the shift toward myocytes ([@bib27]). Therefore, the enrichment for such genes in *Kmt2b*^*−*/−^ PSA-NCAM^−^ cells indicates that loss of KMT2B prevents their expected silencing, rerouting conversion toward alternative fates.

Consistent with this observation, the top gene ontology (GO) enrichments of upregulated genes in *Kmt2b*^*−*/−^ PSA-NCAM^−^ cells were all related to myocyte fate acquisition and function ([Figure 3](#fig3){ref-type="fig"}E). Moreover, among these genes, we scored a 35-fold increase in *MyoD1*, a fundamental driver of myogenic differentiation ([@bib23]; [Figure 3](#fig3){ref-type="fig"}F).

Because we observed a very high correlation in fold changes between the transcriptomes (correlation \[cor\] ∼ 0.8, p ∼ 2e−16) of PSA-NCAM^+^ and PSA-NCAM^−^ fractions ([Figure 4](#fig4){ref-type="fig"}A), we hypothesized that much of the impairment in *Kmt2b*^−/−^ transcriptomic resetting occurred early during MEF-to-iN transition. Thus, we analyzed the genes that changed in the same direction in both PSA-NCAM fractions and whose level of expression is regulated during transdifferentiation ([@bib30]). Indeed, most of the genes downregulated in the absence of KMT2B in both fractions are upregulated in the first phases of transdifferentiation ([Figure 4](#fig4){ref-type="fig"}B), and among them, we found the genes of the maturation subnetwork, *Zfp612*, *Arnt2,* and *Lass4*. In particular, *Arnt2* and *Zfp612* are upregulated or remain expressed only when MEFs are transduced with either *Brn2* or *Myt1l* or all BAM factors but not with *Ascl1* alone. Hence, in the absence of KMT2B, these genes could not be activated despite the presence of *Brn2* and *Myt1l*. Furthermore, one of the main direct targets of ASCL1, the repressor ZFP238 ([@bib30]), was deregulated both in PSA-NCAM^+^ and PSA-NCAM^−^ *Kmt2b*^−/−^ fractions with respect to controls ([Figure 4](#fig4){ref-type="fig"}B), underscoring that the loss of KMT2B disrupts the dynamic interplay among BAM factors on their targets.Figure 4Early Dysregulation of MEF-to-iN Conversion in the Absence of KMT2B(A) Correlation of fold changes in *Kmt2b*^−/−^ across PSA-NCAM^−^ and PSA-NCAM^+^ cells. All tested genes are plotted.(B) Heatmap of expression across normal transdifferentiation (left) and on day 13 (right) of DEGs with genome-wide significance in both cell fractions and also significantly differentially expressed during normal transdifferentiation. *Z* scores were calculated separately for the left and right portions of the heatmap.

Together, the combined transcriptomic analysis of PSA-NCAM^+^ and PSA-NCAM^−^ cKO and control cells demonstrates that, upon transdifferentiation, *Kmt2b*^−/−^ MEFs undergo an early massive dysregulation of the transcriptional program enabling conversion. This, on one side, leads to a lower transdifferentiation efficiency and a substantial shift toward a myocytic fate; on the other, it prevents the few converting *Kmt2b*^−/−^ cells from activating the full neuronal maturation program.

Elucidation of the KMT2B-Vulnerable Epigenome {#sec2.4}
---------------------------------------------

Next, we proceeded to analyze how the epigenome resetting underlies MEF-to-iN conversion. To define how KMT2B loss affects the balance between H3K4me3 and histone H3 lysine 27 trimethylation (H3K27me3) deposition at specific loci ([@bib1]), we performed chromatin immunoprecipitation coupled to deep sequencing (ChIP-seq) on MEFs 2 and 7 days after 4-OHT administration. We first observed that most of the genes that were downregulated in both cell fractions (i.e., PSA-NCAM^+^ and PSA-NCAM^−^) were H3K4me3-marked in control MEFs and lost this mark already 2 days after 4-OHT administration in *Kmt2b*^−/−^ MEFs ([Figure 5](#fig5){ref-type="fig"}A). The loss of KMT2B had, instead, a milder effect, and on a smaller proportion of the transcription start site (TSS), for the genes downregulated in PSA-NCAM^+^ cells ([Figures 5](#fig5){ref-type="fig"}A and 5B). Moreover, the decrease in H3K4me3 was accompanied by an increase in H3K27me3 at these TSS, which, already in cKO MEFs before the onset of iN conversion, had a magnitude comparable with the increase observed at 5 days of transdifferentiation ([Figure 5](#fig5){ref-type="fig"}C). This suggests that the epigenome remodeling, which rapidly follows the loss of KMT2B, disfavors MEF-to-iN conversion and, more specifically, that the initial failure of *Kmt2b*^−/−^ MEFs in keeping active a specific subset of genes ([Figure 5](#fig5){ref-type="fig"}C) has a major, very early effect on transdifferentiation efficiency, whereas the effect of *Kmt2b* loss on neuronal maturation likely occurs at later steps.Figure 5The Histone Methylation Patterns of *Kmt2b*^−/−^ MEFs Prefigure Gene Repression in Untransdifferentiated cKO Cells(A) MEF H3K4me3 coverage (in reads per kilobase million \[RPKM\]) in *Kmt2b*^−/−^, control, and double-mutant MEFs 2 and 7 days after the last 4-OHT administration around the TSS of DEGs in *Kmt2b*^−/−^ and control transdifferentiating cells.(B) MEF H3K4me3 RPKM around the TSS of genes downregulated in both PSA-NCAM fractions (left) and in *Kmt2b*^−/−^ PSA-NCAM^+^ cells only (right).(C) H3K27me3 RPKM around the TSS of genes downregulated in *Kmt2b*^−/−^ PSA-NCAM^−^ cells, in MEFs, and at 5 days of transdifferentiation.

Thus, to specifically dissect the epigenome resetting underlying iN maturation, we performed ChIP-seq on control and *Kmt2b*^−/−^ MEFs on days 5 and 13 of transdifferentiation, also including the day 5 *Kmt2a*^−/−^ background.

The *Kmt2a*^−/−^ sample clustered together with controls in the PCA, further demonstrating the lack of effect of the absence of KMT2A on transdifferentiation ([Figure 6](#fig6){ref-type="fig"}A).Figure 6H3K4me3 Remodeling along Neuronal Transdifferentiation and Differentiation(A) PCA across the union of H3K4me3 sites in *Kmt2b*^*−/−*^ and control transdifferentiating MEFs at 5 and 13 days (in the latter after sorting for PSA-NCAM) and in MEFs prior to transdifferentiation.(B) Quilt of the GO enrichment analysis regarding the cellular components of the genes both differentially H3K4 trimethylated and expressed (FDR \< 0.01, fold change \[FC\] \> 0.5) in *Kmt2b*^−/−^ with respect to the control.(C) Correlation of fold change in 13-day *Kmt2b*^−/−^ iNs with fold change in *Kmt2b*^−/−^ hippocampal neurons. Only genes significantly dysregulated in both datasets are plotted.(D) Distribution of fold changes in H3K4me3 in *in vivo Kmt2b*^−/−^ hippocampal neurons ([@bib15]) of sites that lose H3K4me3 in transdifferentiating *Kmt2b*^−/−^ versus control cells.(E) Enrichments for biological processes among genes with decereased H3K4me3 in BAM-treated KO cells but not in CaMKII neurons, against the background of all H3K4me3-marked genes.

As expected by the ChIP-seq on MEFs, for the largest majority of differentially marked regions, the loss of H3K4me3 was maintained from day 5 to day 13, whereas, for a small subset of loci, the loss was reverted on day 13 ([Figure S4](#mmc1){ref-type="supplementary-material"}A). The latter were particularly enriched for genes related to the regulation of nervous system development (2.4-fold enrichment, q ∼ 0.009) and intracellular ligand-gated ion channel activity (15-fold enrichment, q ∼ 0.007), suggesting delayed compensation on a subset of KMT2B targets enabling the acquisition, albeit severely compromised, of neuronal identity.

On the other hand, we identified 112 genes that presented lower H3K4me3 in *Kmt2b*^−/−^ transdifferentiating MEFs already on day 5 and that showed a further decrease in the H3K4me3 level at 13 days. Among these, 47 were also downregulated in 13-day iNs ([Figure S4](#mmc1){ref-type="supplementary-material"}B), indicating that KMT2B is necessary for the maintenance of the mark at these loci and for their sustained activation.

In light of the parallel changes in H3K4me3 on day 5 and 13 revealed by the PCA, we analyzed all samples together, adjusting for the differences linked to time points. Upon loss of *Kmt2b*, we found 994 sites, mapping at the TSS of 545 genes, showing decreased H3K4me3 and 95 sites, mapping at the TSS of 82 genes, presenting an increased H3K4me3. Among the 82 genes, only *Runx1t1* was differentially expressed in *Kmt2b*^−/−^ iNs with respect to controls ([Figure S4](#mmc1){ref-type="supplementary-material"}C).

We found that, of the 545 genes showing a reduced H3K4me3, 143 were significantly differentially expressed, underscoring the critical importance of KMT2B-mediated H3K4me3 deposition as a source of differential expression (overlap, p ∼ 2e−59, hypergeometric test) while extending the observation that only subsets of KMT2B-dependent H3K4me3 targets are transcriptionally vulnerable ([@bib11]). Some of the most significantly enriched GO categories among these genes were related to neuronal cell components (e.g., axon), pointing to a KMT2B-mediated gene expression program whose disruption underlies defective iN specification and maturation ([Figure 6](#fig6){ref-type="fig"}B).

Next, to investigate how the role of KMT2B in transdifferentiation relates to the physiological maintenance of the neuronal fate, we compared the transcriptomic and epigenomic data of *Kmt2b*^−/−^ iNs with those of *in vivo* post-mitotic hippocampal neurons (transcriptomes from whole hippocampi and H3K4me3 profiles from hippocampal neurons, respectively), in which *Kmt2b* loss was driven by Ca2+/calmodulin-dependent protein kinase II (CaMKII)-dependent *Cre* expression ([@bib15]). We observed that the 116 DEGs shared between the two datasets were dysregulated in the same direction (cor p ∼ 9e−7) ([Figure 6](#fig6){ref-type="fig"}C). Indeed, of the sites that lost H3K4me3 in our BAM-treated cKO cells, about 90% were detectable in some of the *in vivo* samples, and of these, 80% also showed a reduction in H3K4me3 in *Kmt2b*^−/−^ hippocampal neurons ([Figure 6](#fig6){ref-type="fig"}D). Thus, loss of *Kmt2b* affects a core set of sites that lose H3K4me3 independently of the stage of neuronal determination, pointing to a fundamental convergence between the processes of iN conversion and the maintenance of physiologically acquired neuronal fate. Instead, the genes that lost the mark only in the transdifferentiation paradigm presented an enrichment for positive regulation of both neurogenesis and cell projection organization, concordant with the specific features of our impaired conversion process ([Figure 6](#fig6){ref-type="fig"}E).

Finally, to discriminate between the direct versus indirect KMT2B targets underlying the impaired transcriptomic remodeling of *Kmt2b*^−/−^ MEF-to-iN transition, we set out to profile its genome-wide occupancy. To circumvent the lack of ChIP-grade commercial antibodies against KMT2B, we immunoprecipitated MENIN, the common subunit exclusive to KMT2A and KMT2B complexes, in both *Kmt2a*^+/+^*Kmt2b*^+/+^ and *Kmt2b*^−/−^ transdifferentiating MEFs on day 5. We could thus ascribe MENIN targets in control samples to both methylases, whereas we defined by subtraction, as KMT2B-specific targets, the genes that lost MENIN binding in *Kmt2b*^−/−^ with respect to control cells.

Although the low enrichment of the immunoprecipitation (IP) could only afford limited sensitivity, we could nevertheless identify candidate regions with reduced MENIN enrichment, which we intersected with promoters of genes downregulated and losing H3K4me3 in *Kmt2b*^−/−^ iNs with respect to controls. This revealed a core of 12 candidate direct KMT2B target genes during iN transition ([Figure S5](#mmc1){ref-type="supplementary-material"}). Importantly, these candidate direct targets included, again, *Arnt2*, a central gene of the maturation subnetwork ([@bib27]) that, together with *Gnao1*, *Chst10*, *Rtn1*, and *Gpr135*, is related to neuronal specification, function, and metabolism.

*Kmt2b* Vulnerability Uncovers Candidate Genes Associated with Dystonia {#sec2.5}
-----------------------------------------------------------------------

It was recently shown that *KMT2B* mutations can cause early-onset dystonia ([@bib22], [@bib32]), a neurological disorder whose additional genetic causes remain still largely unknown. Indeed, the DEGs in our *Kmt2b*^−/−^ samples were enriched for genes whose disruption in the mouse is associated with dystonia (*Atp1a3*, *Tubb4a*, *Hpca*, and *GnaI*) or myoclonus (*Npas4*, *Scn8a, Nhlrc1*, *Cit*, *Kcnj11*, *Slc7a10*, *Bsn*, *Mfsd8*, *Kcna1*, and *Plaur*) (5.7-fold, p ∼ 0.0027). Thus, we exploited the 216 candidate direct KMT2B targets predicted by the intersection of DEGs (at FDR \< 0.05) and genes that show H3K4me3 reduction in *Kmt2b*^−/−^ over controls. In particular, we combined these targets with an analysis of genetic variations detected through high-throughput sequencing of whole exome-captured DNA from 225 dystonia patients to define candidate dystonia-relevant gene variants.

First, the analysis of the exome aggregation consortium (ExAC) population data revealed that 45 of 216 targets (21%) exhibited probability of being loss-of-function-intolerant (pLI) scores of 0.9 or higher, 54 (25%) missense *Z* scores of 2.0 or higher, and 26 (12%) both pLI scores of 0.9 or higher and missense *Z* scores of 2.0 or higher ([@bib18]; [Table S2](#mmc2){ref-type="supplementary-material"}). Within all targets, 34% of KMT2B target genes were evolutionary constrained against at least one class of functional variation in ExAC ([@bib18]), indicating that the KMT2B-sensitive gene set is enriched for a genomic sequence in which mutational changes are scarcely tolerated. For most of the KMT2B targets (79%), we found no known disease annotation (monogenic disease) in the OMIM database ([Table S2](#mmc2){ref-type="supplementary-material"}).

Under an autosomal dominant disease model, whole-exome sequencing (WES) yielded 38 unique, predicted deleterious missense variant across 32 KMT2B targets, 1 each in 38 independent probands. Of these variants, 11 affected genes with a selective constraint against missense variation (missense *Z* scores ≥ 2.0). Six genes contained heterozygous missense variants in more than 1 proband (*ALK*, *DOCK10*, *KDR*, *LRP2*, *SLC35F1*, and *SLC40A1*). In addition, a total of 7 unique predicted loss-of-function variants affecting 7 KMT2B targets were identified among 7 separate probands. Of these variants, 1 resided in a gene with strong loss-of-function intolerance in the general population (*NOL4*, pLI score of 1.0). Four variants in 3 genes emerged as especially promising candidates for follow-up evaluation ([Table 1](#tbl1){ref-type="table"}). In a female proband with childhood-onset segmental isolated dystonia and a family history suggestive of dominant inheritance (case_224), we detected a c.457C \> T (p.Arg153X) stop-gain variant in the *NOL4* gene whose haploinsufficiency is predicted to be non-tolerable (pLI score of 1.0) ([@bib18]); two male probands with a strikingly similar presentation of early adulthood-onset tremulous cervical isolated dystonia were each identified to have a distinct missense variant of the exact same codon 51 in *SLC35F1* (case_112: c.152G \> T \[p.Arg51Met\]; case_122: c.152G \> C \[p.Arg51Thr\]), a gene constrained against missense variants (missense *Z* scores of 2.01) ([Figure S6](#mmc1){ref-type="supplementary-material"}B); and a female proband manifesting late adulthood-onset cervical isolated dystonia (case_088) was found to harbor a missense variant at *SLC40A1* codon 157 (c.469G \> C \[p.Asp157His\]) ([Figure S6](#mmc1){ref-type="supplementary-material"}C). Along with the observation that other missense mutations at this site have been implicated in hemochromatosis type 4 (MIM606069) ([@bib3], [@bib9]), a multisystem iron deposition disorder, this finding led us to reverse-phenotype this proband and uncover elevated serum ferritin levels as well as bilateral signal alterations on brain MRI in a pattern consistent with brain iron deposition (data not shown). Finally, to complete a comprehensive assessment of the mutational architecture in *KMT2B* targets among dystonia cases, we analyzed two additional murine datasets of KMT2B-vulnerable genes from brain neurons ([@bib14]) and ESCs ([@bib5]), respectively ([Table S3](#mmc3){ref-type="supplementary-material"}), scoring them against the same panel of 225 exomes from dystonia patients. We found that the deletion of *Kmt2b* in these different cellular systems led to the identification of different targets and that the percentage of candidate dystonia-causative genes was different in the three cellular types. Specifically, the percentage of dystonia candidate genes was significantly higher in the iN versus ESC set of KMT2B targets for pLi score ([Table S4](#mmc1){ref-type="supplementary-material"}), suggesting that transdifferentiation uncovers greater vulnerability in the KMT2B-dependent pathways at play in dystonia.Table 1Candidate variants in 4 probands with dystoniaDisease modelGenepLI score (ExAC)missense Z score (ExAC)Known disease annotation (OMIM)Variation nucleotide[a](#tblfn1){ref-type="table-fn"}Variation amino acid[a](#tblfn1){ref-type="table-fn"}Variant typeFrequency ExAC; dbSNP142Frequency in-house exomes[b](#tblfn2){ref-type="table-fn"}CADD scoreCarrier \#SexAge at onset, yDystonia typeFamily historyComment on putative disease relevanceAutosomal-dominant*NOL4*1.02.7noc.457C\>Tp.Arg153Xstop-gainnot found; not foundnot found37case_224F4segmental isolated dystonia (cervical dystonia, upper limb dystonic tremor)positiveloss-of-function variant in gene with pLI≥0.9Autosomal-dominant*SLC35F1*0.392.01noc.152G\>Tp.Arg51Metmissensenot found; not foundnot found30case_112M26focal isolated dystonia (tremulous cervical dystonia)negativemutational recurrence at codon-51 in gene with missense Z score ≥2.0Autosomal-dominant*SLC35F1*0.392.01noc.152G\>Cp.Arg51Thrmissensenot found; not foundnot found24case_122M33focal isolated dystonia (tremulous cervical dystonianegativemutational recurrence at codon-51 in gene with missense Z score ≥2.0Autosomal-dominant*SLC40A1*0.981.77MIM606069c.469G\>Cp.Asp157Hismissensenot found; not foundnot found31case_088F44focal isolated dystonia (cervical dystonia)positivemutational recurrence at codon-157, a site previously associated with hemochromatosis 4[^6][^7][^8]

Discussion {#sec3}
==========

Here, we showed that KMT2B is required for the BAM-mediated epigenome remodeling that underlies the MEF-to-iN conversion and that the molecular unravelling of this phenotype exposes dystonia candidate genes. In particular, we demonstrated, for KMT2B, a dual role in the promotion of iN conversion through suppression of the alternative myocytic fate as well as in iN maturation. In contrast, KMT2A proved dispensable and, despite being a paralog of KMT2B, was unable to replace it in transdifferentiation. Beyond identification of the first chromatin regulator essential for MEF-to-iN conversion, our findings support the following conclusions about the specificity of direct neuronal programming.

First, the requirement for KMT2B in iN generation only partially recapitulates its function during both *in vitro* and *in vivo* neuronal differentiation. *In vitro*, *Kmt2b*^−/−^ ESCs present an impaired differentiation to neurons ([@bib20]), whereas the deletion of *Kmt2b* in excitatory forebrain terminally differentiated neurons did not impinge brain morphology macroscopically but impaired memory formation and affected H3K4me3 deposition ([@bib14], [@bib15]). This notwithstanding, we found high convergence in vulnerable H3K4me3 sites upon loss of KMT2B between *in vivo* matured neurons and transdifferentiated iNs. Conversely, the dispensability of KMT2A in MEF transdifferentiation stands in stark contrast with its essential role during neuronal differentiation, as observed both in murine SVZ ([@bib19]) and in *D. rerio* ([@bib12]). Together, these results highlight how different origins and/or transition paths to similar developmental endpoints (namely, transdifferentiation and differentiation) expose distinct epigenetic requirements. This, in turn, has major implications for the choice of programming or reprogramming paradigms in disease modeling and regeneration, especially when they are intended to model or remedy deficits in epigenetic regulation.

Second, we previously showed that the defective response to lipopolysaccharide (LPS) in *Kmt2b*^−/−^ macrophages was imputable to a single downstream gene, *Pigp*, which aberrantly accumulated H3K27me3 ([@bib1]). In MEF-to-iN transition, instead, we found that loss of KMT2B leads to massive transcriptional dysregulation and H3K4me3 redistribution that affects, starting already at the MEF level, the whole program of iN fate acquisition and maturation rather than specific master regulators, pointing to distinct logics of cell fate control downstream of the same chromatin modifier.

Third, the presence of H3K4me3 at lineage-specific genes has been recently proposed as a molecular roadblock to reprogramming in the nuclear transfer (NT) paradigm ([@bib10]), leading to a model in which H3K4me3-dependent memory of transcriptional status in donor cells limits the reprogramming of their developmental potential. H3K4me3 inhibition in somatic cells thus favors their reacquisition of pluripotency but disables their ability to undergo inter-lineage cell conversion. Because the H3K4me3 inhibition upon NT was carried out by overexpressing the H3K4 demethylase *Kdm5b*, likely its global effects are neither directly comparable with nor symmetrical to our setting, in which the bulk H3K4me3 axis (operated by KMT2E and KMT2F) was left intact. It is worth noting, however, that inhibition of H3K4 demethylase LSD1 (KDM1A) promotes TF-induced reprogramming to pluripotency ([@bib2]). Thus, this symmetrical convergence with our findings points to a fundamental distinction in how NT- versus TF-based reprogramming handles H3K4me3 dynamics.

Finally, our work innovatively exploited transdifferentiation as a tool for the identification and prioritization of candidate causative variants. Because *KMT2B* loss-of-function mutations lead to dystonia ([@bib22], [@bib32]), we reasoned that the KMT2B-vulnerable targets exposed through the MEF-to-iN transition could guide our search for dystonia-relevant variants and genes in whole-exome sequences of dystonia patients. Indeed, we found, in 39 KMT2B targets, 45 unique protein-impactful alterations, including mutations in 3 promising candidates: *NOL4*, *SLC35F1*, and *SLC40A1*. *NOL3*, notable for its relationship to *NOL4*, has been previously associated with myoclonus ([@bib24]), whereas for *SLC35F1*, we found a mutational recurrence at the same codon in 2 probands with very similar phenotypes. Finally, for *SLC40A1*, we scored a mutational recurrence at a codon previously associated with hemochromatosis type 4 and, therefore, with iron deposition. The proband was found to have elevated serum ferritin and possibly iron deposits on brain MRI (bilateral signal alterations of basal ganglia), in line with signal alterations of basal ganglia described in most *KMT2B*-mutated patients ([@bib22]) that had not yet been associated with iron deposits, raising the intriguing possibility that the brain signal alterations seen in KMT2B probands might be due to iron abnormalities induced by SLC40A1-mediated downstream effects. Together, these data offer a compendium of promising candidates that are now opened up for further validation, following the recent trend in human genomics in which mutations originally uncovered in single individuals are eventually consolidated in the definition of syndromes ([@bib29], [@bib7]).

Experimental Procedures {#sec4}
=======================

MEF Derivation {#sec4.1}
--------------

MEFs were derived from mice with cKO for *Kmt2a* ([@bib16]), *Kmt2b* ([@bib8]), or both methylases and housed and bred in a specific pathogen-free animal house. Control MEFs were derived from *Kmt2*^+/+^*YFP*^+^*Cre*^+^ embryos and, in the case of *Kmt2a*, also from *Kmt2a*^fl/+^*YFP*^+^*Cre*^+^ ones. See the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for further details.

Mouse Experiments {#sec4.8}
-----------------

Experiments involving animals were carried out in accordance with the Italian Law (D.lgs. 26/2014) that enforces Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010, on the protection of animals used for scientific purposes. The project started before the passing of D.lgs. 26/2014 and was thus notified to the Ministry of Health before the implementation of the current legislation. As the new legislation does not apply to projects approved before its enactment, for such projects only a notification of the experiments to the Ministry of Health was required (in accordance with the D.L.vo 116/92 \[and following additions\], which enforced EU 86/609 Directive), and this requirement was dutifully fulfilled. Following the coming into force of Italian Law (D.lgs. 26/2014) and the expiration of the previously notified project, we submitted for the continuation of the project a new application to the Ministry of Health that granted us the authorization under Project n 385/2016.

Immunofluorescence {#sec4.2}
------------------

MEFs were seeded with different cell densities in Nunc Lab-Tek Permanox chamber slides (Sigma-Aldrich) in duplicates. 3 and 13 days after plating for transduction, cells were stained and acquired with a BX61 upright microscope equipped with a motorized stage from Olympus. The software ScanR (Olympus) was used, and the objective utilized was 20× with a 0.75 numerical aperture. See the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for further details.

Cytofluorimetric Analysis {#sec4.3}
-------------------------

The PSA-NCAM antibody used is listed in [Table S7](#mmc1){ref-type="supplementary-material"}. 3 min before each tube was acquired, 5--10 μL of propidium iodide (PI) (Sigma-Aldrich, P4170-1G) was added. Samples were acquired at BD FacsCalibur with the BD CellQuest Pro software and analyzed with the Flowjo software. Unpaired t test was executed. See the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for further details.

FACS {#sec4.4}
----

FACS was executed on 4-OHT-treated MEFs left in culture 7 days before transdifferentiation. MEFs were plated on Matrigel-coated dishes both for RNA-seq and the ChIP-seq on iNs at 13 days. Cells were sorted for PSA-NCAM positivity at MoFlo Astrios (Beckman Coulter) with the software Summit v6.2. The negative PSA-NCAM fraction was kept as well.

RNA-Seq {#sec4.5}
-------

RNA was extracted with the RNeasy micro kit (QIAGEN). RNA quality was evaluated with the Agilent 2100 Bioanalyzer. Total RNA was depleted of rRNA with Ribo-Zero, and libraries were prepared with the TruSeq Stranded Total RNA Sample Preparation Kit (Illumina) starting from 100 ng of RNA per sample and sequenced with the Illumina HiSeq machine at a read length of 100 bp, paired ends, and a coverage of 120 million reads. See the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for further details.

ChIP-Seq {#sec4.6}
--------

ChIP-seq for MENIN was performed on bulk 5-day transdifferentiating MEFs, ChIP-seq for H3K4me3 on MEFs 2 and 7 days after the last 4-OHT administration, on the whole-cell population at 5 days, and on PSA-NCAM^+^ cells at 13 days. H3K27me3 ChIP-seq was performed on MEFs 2 and 7 days after the last 4-OHT administration and on the whole-cell population at 5 days. See the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for further details.

Exome Analysis {#sec4.7}
--------------

WES and analysis of all 225 dystonia subjects was performed as described previously ([@bib32], [@bib33]). Assuming that causative mutations in the proband cohort are coding alleles of strong effect, we searched the full WES dataset for missense, in-frame insertion or deletion (indel), stop-gain and stop-loss, frameshift, and splice site variations in any of the KMT2B-sensitive genes ([Figure S6](#mmc1){ref-type="supplementary-material"}A). Filtered variants were considered under both an autosomal dominant (1 heterozygous variant per gene per proband) and an autosomal recessive disease model (homozygous variant or 2 heterozygous variants per gene per proband). See the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for further details.

Ethics Approval {#sec4.9}
---------------

Recruitment of dystonia patients and genetic analyses were performed after approval by the local ethics review boards at each participating center. All dystonia patients provided written informed consent.

Data and Software Availability {#app3}
==============================

The accession number for the sequencing data reported in this paper is GEO: [GSE120441](ncbi-geo:GSE120441){#intref0010}.
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